DAMORA THERAPEUTICS, INC. Cash and Restricted Cash
DAMORA THERAPEUTICS, INC. (DMRA) had Cash and Restricted Cash of $540.51 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-10
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $540.51M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $532.90M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $257.62M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7.61M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $540.51M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $532.90M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $257.62M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $7.61M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $10.21M 10-Q · filed 2026-08-10 |
| 2025-03-31 | $11.94M 10-Q · filed 2026-05-12 |
| 2024-12-31 | $14.18M 10-Q · filed 2026-08-10 |
| 2024-09-30 | $19.68M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $22.86M 10-Q · filed 2025-08-05 |
| 2024-03-31 | $21.09M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $21.46M 10-K · filed 2026-03-19 |
| 2023-09-30 | $23.08M 10-Q · filed 2024-11-01 |
| 2023-06-30 | $22.96M 10-Q · filed 2024-08-12 |
| 2023-03-31 | $25.07M 10-Q · filed 2024-04-29 |
| 2022-12-31 | $32.79M 10-K · filed 2025-03-19 |
| 2022-09-30 | $28.34M 10-Q · filed 2023-11-06 |
| 2022-06-30 | $29.80M 10-Q · filed 2023-07-31 |
| 2022-03-31 | $45.39M 10-Q · filed 2023-04-28 |
| 2021-12-31 | $62.56M 10-K · filed 2024-03-08 |
| 2021-09-30 | $66.16M 10-Q · filed 2022-11-08 |
| 2021-06-30 | $68.64M 10-Q · filed 2022-07-29 |
| 2021-03-31 | $74.45M 10-Q · filed 2022-04-29 |
| 2020-12-31 | $163.84M 10-K · filed 2023-03-09 |
| 2020-09-30 | $85.57M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $36.07M 10-Q · filed 2021-08-05 |
| 2020-03-31 | $43.01M 10-Q · filed 2021-05-04 |
| 2019-12-31 | $11.53M 10-K · filed 2022-02-17 |
| 2019-09-30 | $14.92M 10-Q · filed 2020-12-11 |
| 2018-12-31 | $31.13M 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |